Expert consensus on the follow-up management of bronchopulmonary dysplasia in preterm infants after discharge.
10.7499/j.issn.1008-8830.2201078
- Collective Name:Neonatal Evidence-Based Medicine Group, Committee of Neonatal Medicine, Cross-Straits Medicine Exchange Association
- Publication Type:Journal Article
- Keywords:
Bronchopulmonary dysplasia;
Expert consensus;
Follow-up;
Preterm infant
- MeSH:
Bronchopulmonary Dysplasia/therapy*;
Consensus;
Follow-Up Studies;
Humans;
Infant;
Infant, Newborn;
Infant, Premature;
Patient Discharge;
Quality of Life
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(5):455-465
- CountryChina
- Language:Chinese
-
Abstract:
Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in preterm infants and seriously affects the quality of life of preterm infants. BPD is a life-threatening disease to preterm infants and may lead to serious sequelae including feeding difficulties, recurrent lower respiratory tract infection, airway hyperreactive diseases, growth retardation, and neurodevelopmental delay. In order to further standardize the follow-up management of preterm infants with BPD after discharge, based on related clinical evidence in China and overseas and practice experience, the Neonatal Evidence-Based Medicine Group, Committee of Neonatal Medicine, Cross-Strait Medical and Health Exchange Association, formulated this expert consensus from the aspects of the follow-up and management of respiratory diseases, growth and development, pulmonary hypertension, nerve dysplasia, metabolic bone disease, and vaccination of preterm infants with BPD after discharge.
